Abe Yasunobu, Shiratsuchi Motoaki, Nagasawa Eriko, Ohtsuka Rie, Kiyasu Junichi, Sada Eriko, Idutsu Kensaku, Kotoh Kazuhiro, Nishimura Junji, Ohga Shouichi, Takayanagi Ryoichi
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University.
Rinsho Ketsueki. 2010 Jan;51(1):74-9.
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is more common in children, and is characterized by pancytopenia, liver dysfunction and coagulopathy caused by interactions between EBV-infected T cells and activated macrophages. We describe here five adults with EBV-HLH. The median age was 17 years (range 16 approximately 40). HLH developed in 4 patients within 2 months after the primary infection, and in the other one during the reactivation. All patients had a high EBV viral load in peripheral blood (2 x 10(2)-3 x 10(6) copies/ml) and monoclonal proliferation of EBV-infected T cells. All patients received immunosuppressive therapy with or without etoposide, and two patients required plasmapheresis due to the severity. Three patients are alive in complete remission (follow up periods; 13, 19, 30 months), while two patients became refractory to chemo-immunotherapy and died despite multidrug chemotherapy. EBV-HLH should be more widely recognized in adults in order to achieve early diagnosis and appropriate treatment.
爱泼斯坦-巴尔病毒相关噬血细胞性淋巴组织细胞增生症(EBV-HLH)在儿童中更为常见,其特征是由EBV感染的T细胞与活化的巨噬细胞相互作用导致的全血细胞减少、肝功能障碍和凝血功能障碍。我们在此描述5例成人EBV-HLH患者。中位年龄为17岁(范围16至约40岁)。4例患者在初次感染后2个月内发生HLH,另一例在病毒再激活期间发病。所有患者外周血中EBV病毒载量均较高(2×10²至3×10⁶拷贝/毫升),且存在EBV感染T细胞的单克隆增殖。所有患者均接受了免疫抑制治疗,部分联合依托泊苷,2例病情严重的患者需要进行血浆置换。3例患者存活且完全缓解(随访期分别为13、19、30个月),而2例患者对化疗免疫治疗无效,尽管接受了多药化疗仍死亡。为了实现早期诊断和恰当治疗,成人EBV-HLH应得到更广泛的认识。